Ecstasy Effect on Terminal Cancer Patients to be Tested 1/7/05
http://stopthedrugwar.org/chronicle/369/estudy.shtml
The Food and Drug Administration has approved a pilot study to examine whether MDMA, better known as Ecstasy, can help terminal cancer patients come to grips with end-of-life anxiety and depression. The study, led by Harvard Medical School researcher Dr. John Halpern, is set to begin this spring with 12 cancer patients in the Boston area.
After a virtual ban on psychedelic research dating back to another Harvard researcher, Timothy Leary, the Harvard study marks the second time in a few months that the FDA has approved research into the use of Ecstasy for therapeutic purposes. Last year, the agency gave final approval to a South Carolina study of Ecstasy's efficacy in treating patients with post-traumatic stress disorder. Other studies testing the efficacy of psilocybin, the active ingredient in psychedelic mushrooms, for people with anxiety and obsessive-compulsive disorders are also underway.
According to Dr. Halpern, Ecstasy is an "empathogen," a substance that can reduce stress and increase empathy. Unlike LSD, said Halpern, Ecstasy is "ego friendly," and unlike many pain medications, it does not make people groggy or over-sedated. Instead, according to anecdotal reports, people with terminal illnesses who have taken the drug found it easier to talk to friends and families about death and other uncomfortable subjects. "End of life issues are very important and are getting more and more attention, and yet there are very few options for patients who are facing death," he said.
|
 |
|
The MAPS Bulletin |
The study is being sponsored by the Multidisciplinary Association for Psychedelic Studies (http://www.maps.org).
The discoverer of LSD, Dr. Albert Hoffman, who turns 99 this month, referred to the substance as "my problem child." But Hoffman remains convinced that psychedelics like LSD can have positive therapeutic effects.
Dr. Charles Grob, a psychiatrist at the Harbor-UCLA Medical Center in Los Angeles who is leading an FDA-approved study of the efficacy of psilocybin in helping terminal cancer patients deal with end-of-life emotional and spiritual issues, told the Washington Post that, if used in a therapeutic setting, psychedelics can yield impressive results.
Grob's patients, who take "modest" doses of synthetic psilocybin and then spend the next few hours in a comfortable setting with a psychiatrist, are doing well, he said. "So far they have had impressive results in terms of amelioration of anxiety, improvement of mood, increased rapport with family and friends and, interestingly, significant and lasting reductions in pain. These are extraordinary compounds that seem to have an uncanny ability to reliably induce spiritual or religious experiences."
Dr. Halpern, who will lead the Boston study, told the Post psychedelics "may be helpful" for many facing death. "For a lot of people, the anxiety about death is so tremendous there is no way to get their arms around the problems that were ongoing in their families. This could be a substantial contribution to the range of palliative care strategies we're trying to develop for people facing death."
Recent Comments